Please assess the completion status of the following clinical trial:

Trial Title: Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with histologically confirmed de novo DLBCL (CD20 positive) (cf section 20.6 - Appendix 4)~2. Age between 60 and 80 years included, on the day of the informed consent document signature~3. Age adjusted International Prognosis Index (aaIPI) score ≥ 1~4. No prior treatment for DLBCL. However prephase treatment with 1mg/kg/day prednisone or equivalent, for a maximum of 14 days, is permitted prior to begin the treatment~5. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 (0 or 1 only for phase 1b)~6. Life expectancy of ≥ 90 days (3 months) before starting Entospletinib~7. Signed informed consent~8. At least one bi-dimensionally measurable lesion defined as at least one node or tumor lesion on CT scan ≥ 1.5 cm~9. fluorodeoxyglucose (FDG) positron emission tomography (PET-CT) performed at baseline with a FDG positive result~10. Adequate hematologic functions defined as follows (unless secondary to bone marrow involvement by lymphoma):~    * Absolute neutrophil count (ANC) \> 1.5 X 10\^9 G/l and~   * Platelets count ≥ 75 X 10\^9/l without platelet transfusion dependency during the last 7 days and~   * Haemoglobin level \> 9 g/dl (may receive transfusion)~11. Adequate liver function defined as follows:~    * Total bilirubin \<1.5 upper limit of normal (ULN) except for unconjugated hyperbilirubinemia of Gilbert's syndrome and~   * Alkaline phosphatase (in absence of bone disease), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 3 X ULN~12. Adequate renal function as calculated by a creatinine clearance \> 40 ml/min by local institutional formula~13. Patients with prior Hepatitis B must be given antiviral prophylaxis and hepatitis B virus (HBV) DNA monitored; Patients with prior Hepatitis C are eligible if, hepatitis C virus (HCV) RNA is undetectable.~14. Left ventricular ejection fraction (LVEF) ≥ 50% of echocardiography or multiple gated acquisition (MUGA) scan~15. Adequate tissue for central retrospective testing for cell of origin (10-15 slides of tumor biopsy must be available at baseline)~16. Heterosexually active females of childbearing potential (as defined in the protocol) must:~    * have a negative serum pregnancy test at baseline and prior to the first study drug administration (C1D-4)~   * have practiced at least 1 reliable method of contraception for at least 2 months prior to the first study drug administration (C1D-4)~   * agree to utilize highly effective methods of contraception (as defined in the protocol) from Cycle 1 Day -4 until 12 months following the last treatment administration~17. Heterosexually active males with partners of childbearing potential must agree to use reliable forms of contraception during treatment and up to 12 months after last treatment administration~18. Male subjects must agree to avoid sperm donation from Cycle 1 Day -4 until 12 months following the last treatment administration~Exclusion Criteria:~1. Central nervous system or meningeal involvement with DLBCL~2. Contraindication to any drug contained in the chemotherapy regimen~3. Prior treatment with Entospletinib or other spleen tyrosine kinase (SYK ) inhibitor~4. Patients with a prior history of other malignancy, exceptions include:~   * a subject who has been disease-free after curative local treatment (surgical resection) for at least 3 years,~  * a subject with a history of a completely resected non-melanoma skin cancer or in situ carcinoma with surgical complete excision.~5. Patients taking current therapy with proton pump inhibitors and current therapy with medicines that are strong Cytochrome P450 3A (CYP3A) or CYP2C9 inducers, or moderate CYP2C9 inducers.~6. Ongoing active pneumonitis~7. Peripheral sensory or motor neuropathy grade \> 1.~8. Major surgery within 4 weeks before first dose of study drug (minor procedures including transcutaneous biopsy, central line placement are permitted at any time)~9. Inability to take oral medication or malabsorption syndrome or any other uncontrolled gastrointestinal condition that would impair ability to take entospletinib~10. Significant cardiovascular impairment: congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction or stroke within 6 months of first dose of entospletinib or ventricular arrhythmia~11. Active infection as judged by the investigator~12. Known hypersensitivity to ENTO~13. Congenital immunodeficiency or known HIV (human immunodeficiency virus infection) or active viral hepatitis B or C~14. Any other major illness that in the investigator's judgement, will substantially increase the risk associated with the subject's participation in the study~15. Subjects who have undergone a solid organ transplant and stem cell transplant~16. Previous treatment for B cell lymphoma or Richter's transformation~17. Primary Mediastinal B Cell Lymphoma

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Experimental (Type: EXPERIMENTAL): Entospletinib + Rituximab + Cyclophosphamide + Doxorubicine + Vincristine + Prednisone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy